77 results about "Lactobacillus johnsonii" patented technology

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composite sleep-aiding composition based on agilawood and a preparation method thereof. The preparation method comprises the following steps: carrying out ultrasonic-assisted enzymolysis on agilawood by adopting amylase and cellulase, carrying out mixed fermentation on the agilawood subjected to enzymolysis by inoculating lactobacillus plantarum, lactobacillus johnsonii and saccharomyces cerevisiae, and carrying out sterilization, filtration, concentration and drying treatment on the fermented agilawood to obtain the agilawood fermentation product. According to the method, the release rate of active substances in the agilawood is increased, the composite sleep-aiding composition containing the agilawood fermentation product has a remarkable sleep-aiding effect, the preparation method is simple, the problem that an existing agilawood product is poor in sleep treatment effect is solved, and the agilawood fermentation product is safe, free of irritation and high in application value.

The invention belongs to the technical field of cosmetic raw materials, and particularly provides a composition containing kava pepper and mung bean seed extracts, a preparation method and application. The preparation method of the mung bean seed extract is specifically optimized, for example, a lactobacillus plantarum strain, a lactobacillus johnsonii strain and a lactobacillus acidophilus strain are compounded and used for fermenting sprouted mung bean liquid, and a fermentation culture medium, fermentation environment conditions and the like are optimized; the nutritional ingredients of protein, glycine, inorganic salt and the like in the prepared mung bean seed extract are effectively improved, so that the prepared composition containing the kava pepper and the mung bean seed extract and the cosmetics thereof can show excellent effects of moisturizing and repairing, resisting inflammation, resisting aging, instantly calming, easing pain and the like.

The invention discloses an application of probiotics in preparation of a medicine for preventing and / or treating cholestatic liver diseases. The probiotics are selected from one or more of plant lactobacillus Lp-G18, bifidobacterium longum subsp. Longum BL-G301, lactobacillus reuteri LR-G100 and lactobacillus johnsonii LJ-G55. Preferably, the cholestatic liver disease is primary biliary cholangitis.

The invention belongs to the field of functional composite microbial preparations, and particularly discloses a microbial agent and GABA compounded composition and application thereof in promoting growth and development of children. The composition is prepared from a freeze-dried bacterial agent and a GABA (gamma-aminobutyric acid) compound, wherein the freeze-dried bacterial agent comprises lactobacillus johnsonii YH1136 and lactobacillus helveticus Helveticus; the GABA compound is prepared by loading GABA with the purity of greater than or equal to 98% on a nano cellulose carrier, and the loading rate is 20-35%. The composition realizes high survival rate of the microbial inoculum and targeted slow release of GABA through a freeze-drying process and enteric coating. Experiments show that the composition can significantly improve the serum GH / IGF-1 level, the bone mineral density and the body growth rate, and has a synergistic effect when combined with the vitamin D3. According to the invention, the problems of single strain function, low GABA utilization rate and gastric acid damage in the prior art are solved, and an efficient and safe solution is provided for children growth and development intervention.

The invention discloses lactobacillus johnsonii A21065 capable of resisting oxidation, prolonging life and delaying Parkinson's disease as well as a product and application of the lactobacillus johnsonii A21065, and belongs to the technical field of functional strains. The preservation number of the lactobacillus johnsonii A21065 is GDMCC (China General Microbiological Culture Collection Center) No: 65767. In a caenorhabditis elegans model, the lactobacillus johnsonii A21065 shows that the lactobacillus johnsonii A21065 has better effects of improving the oxidation resistance of nematodes, resisting environmental stress and prolonging the life, also shows a good effect in in-vitro experiments of resisting artificial gastrointestinal fluid, resisting cholate and the like, meanwhile, the lactobacillus johnsonii A21065 also has an effect of improving the cognition of a Parkinson nematode model, and the lactobacillus johnsonii A21065 has a good application prospect. The invention has important significance for preventing and / or treating Parkinson's disease.

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

An Akk11 strain-containing probiotic agent capable of relieving hyperuricemia, and the use thereof. Strains in the probiotic agent include an Akkermansia muciniphila Akk11 strain and a Lactobacillus johnsonii LJ09 strain. It is found in the present application that the two strains possess a potential interaction and can cooperate with each other, thereby synergizing the effect of relieving hyperuricemia, which is specifically manifested in: being capable of remarkably regulating uric acid metabolism and improving renal clearance functions; being capable of effectively inhibiting the activity of a key enzyme for uric acid synthesis so as to reduce the production of uric acid, and being capable of remarkably relieving renal damage and renal dysfunctions associated with high levels of uric acid.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention discloses a cough and asthma relieving composition, and belongs to the field of traditional Chinese medicines. The cough and asthma relieving composition is prepared from traditional Chinese medicine fermented particles, semen armeniacae amarae, folia perillae acutae and radix peucedani, the traditional Chinese medicine fermented particles are prepared from pericarpium citri reticulatae, radix platycodonis and radix glycyrrhizae as raw materials, cellulase is firstly used for conducting enzymolysis on the raw materials to obtain enzymatic hydrolysate, then lactobacillus plantarum, lactobacillus johnsonii and rhodotorula mucilaginosa are used for conducting mixed fermentation on the enzymatic hydrolysate to obtain fermentation liquor, and the fermentation liquor is prepared into the cough and asthma relieving composition. And sterilizing, filtering, drying and granulating the fermentation liquor to obtain the traditional Chinese medicine fermented granules. The traditional Chinese medicine fermented granules provided by the invention are compounded with the semen armeniacae amarae, the folium perillae and the radix peucedani for use, so that a synergistic effect is achieved, and an excellent cough and asthma relieving effect is achieved.

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and / or improving athletic ability.

The method includes the steps of providing a plant protein substrate and fermenting the plant protein substrate with a starter culture containing *Lactobacillus johnsonii*. The invention also relates to plant-based products from such fermentation and *Lactobacillus johnsonii* strains suitable for use in the invention. The invention further relates to peptides that impart and / or enhance rich flavors, methods for preparing such peptides, compositions containing such peptides, and the use of such peptides as flavoring agents.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The invention provides a preparation method of anti-inflammatory soothing and repairing microspheres based on Trichoderma reesei-Lactobacillus johnsonii two-stage fermentation. According to the preparation method, Trichoderma reesei fermentation products, Lactobacillus johnsonii metabolites, specific plant active ingredients and mussel mucoprotein are included. According to the invention, the mussel mucoprotein-trichoderma reesei-lactobacillus johnsonii ternary synergistic anti-inflammatory antibacterial system microspheres are innovatively constructed, the targeted delivery efficiency of active ingredients is remarkably improved through the adhesion characteristic of mussel mucoprotein, and the technical bottlenecks of poor permeability and short action time of a traditional anti-inflammatory preparation are solved. A multi-strain synergistic fermentation process is adopted, beta-glucan secreted by trichoderma reesei and short-chain fatty acid generated by lactobacillus johnsonii generate a synergistic anti-inflammatory effect, and meanwhile, an enzymolysis technology is combined to realize efficient conversion of plant active ingredients, so that the inhibition effect on key inflammatory factors such as TNF-alpha and IL-6 is remarkably enhanced. According to the system, inflammatory pathways such as NF-kappa B and the like are regulated and controlled through multiple targets, the inflammatory reaction is reduced while the growth of pathogenic bacteria is inhibited, a remarkable broad-spectrum antibacterial and anti-inflammatory synergistic effect is shown, and an innovative solution is provided for developing an efficient and safe anti-inflammatory antibacterial preparation.

The invention belongs to the technical field of biology, discloses a method for rapidly and quantitatively detecting viable bacteria of lactobacillus jensenii in a composite viable bacteria medicinal preparation, and particularly discloses a reagent which comprises a primer pair for detecting the lactobacillus jensenii, and the primer pair comprises an upstream primer L.jens-F1 and a downstream primer L.jens-R1. The reagent provided by the invention has good discrimination degree on common strains such as lactobacillus crispatus, lactobacillus reuteri, lactobacillus gasseri, lactobacillus plantarum, lactobacillus fermentum, lactobacillus johnsonii, lactobacillus rhamnosus and lactobacillus delbrueckii in the same genus, and can detect lactobacillus jensenii with high specificity.

The present invention provides an application of lactobacillus in the preparation of a medicine for preventing and / or treating liver and / or kidney and / or bone damage caused by excessive intake of fluoride, and relates to the technical field of lactobacillus application. The present invention achieves the purpose of preventing and / or treating damage to the liver and / or kidney and / or bone by reducing the accumulation of fluoride in the liver and / or kidney and / or bone, and the lactobacillus is Lactobacillus johnsonii BS15. Lactobacillus johnsonii BS15 is used to reduce the accumulation of fluoride in the body, especially in the liver, kidney and bone during high fluoride exposure, improve the damage to organs caused by high fluoride exposure, promote the excretion of fluoride from the body, promote the excretion of fluoride from the kidney, promote the excretion of fluoride in feces and urine, and improve the damage to the liver, kidney, lung and nerve center of mice. It is safe and effective to use, has no toxic side effects, and has a wider application.

The present application relates to lactic acid bacteria with blood sugar lowering function and application thereof, and particularly provides a group of lactic acid bacteria with high safety, which can play an important role in regulating intestinal microecological balance of human body and has blood sugar lowering effect.The lactic acid bacteria is named as Lactobacillus johnsonii 4437-4AT, the strain number is 4437-4AT, and was preserved in Guangdong Microbial Culture Collection Center on January 20, 2026, the preservation address is: No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100 Courtyard, the preservation number is: GDMCC NO: 67710.

The invention discloses a broiler feed additive containing chlorella and application of the broiler feed additive. The additive contains chlorella; the feed also contains one or more of lactobacillus johnsonii, enterococcus faecalis, saccharomyces cerevisiae and bacillus amyloliquefaciens. By adding the additive disclosed by the invention into daily ration, the intestinal tissue form can be improved by regulating antioxidant and immune functions, so that the growth performance of the broiler chicken can be remarkably improved. In the additive, lactobacillus johnsonii BS15 and enterococcus faecalis YP-2 are combined for use, and saccharomyces cerevisiae WHY-7 and bacillus amyloliquefaciens TL are combined for use, so that the average weight of the broiler chicken is increased, the spleen index after LPS stimulation is reduced, and synergistic interaction is achieved.

The invention discloses a lactic acid bacteria composition, lactic acid bacteria fermentation liquor, a lactic acid bacteria agent, fermented milk and a preparation method and application thereof, and belongs to the technical field of microorganisms. The lactobacillus composition disclosed by the invention is prepared from lactobacillus johnsonii S2L, lactobacillus reuteri S5L and lactobacillus mucous membrane mucus S16L; the preservation number of the lactobacillus johnsonii S2L is GDMCC No: 66569; the preservation number of the lactobacillus reuteri S5L is GDMCC No: 66558; the preservation number of the lactobacillus mucous membrane S16L is GDMCC No: 66559. The strains in the lactic acid bacteria composition have excellent probiotic characteristics, do not have virulence factors, are fermented in the milk replacer, are short in fermentation time, can improve the protein hydrolysis degree of the milk replacer, reduce the incidence rate of lamb diarrhea and optimize the intestinal microflora, and have positive effects on improving the feed intake of lambs.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The present invention provides an Anguilla japonica feed composition using a fermented pig blood product, the composition having the effects of promoting the growth of Anguilla japonica, enhancing health, and enhancing feed efficiency. The composition of the present invention comprises a fermented product obtained by inoculating a Lactobacillus johnsonii strain into pig blood and culturing same.

The present application relates to a lactobacillus johnsonii producing a novel class III bacteriocin, an engineered bacterium and application thereof, and belongs to the technical field of microorganisms. Lactobacillus johnsonii The JLJ071 strain of the lactobacillus johnsonii is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.34541. The bacteriocin amino acid sequence is shown in Seq ID No.1. The expressed novel class III bacteriocin has good bactericidal activity on listeria monocytogenes and salmonella pullorum, and has good characteristics such as acid resistance, high temperature resistance and protease resistance, and has a good application prospect in feed additives.

This invention relates to a lactobacillus composition for alleviating atopic dermatitis. This lactobacillus composition comprises at least one of *Lactobacillus johnsonii* strain GKJ2 and *Lactobacillus plantarum* strain GKK1. When administered to subjects suffering from atopic dermatitis for a continuous period, it can regulate Th1, Th2, Treg, and Th17 cellular immunity, alter the intestinal flora, and increase the concentration of short-chain fatty acids in the intestine, thereby alleviating atopic dermatitis. Therefore, this lactobacillus composition can be used as an active ingredient in the preparation of various compositions for alleviating atopic dermatitis.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

The invention discloses Lactobacillus johnsonii and application thereof in alleviating intestinal damage caused by plateau hypoxia. The composite bacterial agent of the composition of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent, treat and alleviate intestinal damage caused by plateau hypoxia exposure. The composite bacterial agent can increase the expression levels of tight junction proteins such as Claudin‑1, Occludin and ZO‑1, and restore the intestinal barrier function damage caused by plateau hypoxia exposure; restore the expression level of intestinal pro-inflammatory cytokines; reduce the level of harmful bacteria Escherichia coli, and increase the level of beneficial bacteria Lactobacillus; improve diarrhea; and maintain body weight. The composite bacterial agent provided by the invention can be used to prepare a medicine for alleviating intestinal damage caused by plateau hypoxia exposure and a composition thereof, can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and can also be used as a microecological preparation in medicines or health products, and has a very broad application prospect.

The invention discloses application of a Lactobacillus johnsonii composite bacterial agent in preparing a drug for preventing and treating memory impairment caused by plateau hypoxia, and belongs to the field of microorganisms. The composite bacterial agent of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent and treat brain memory dysfunction caused by exposure to a plateau hypoxic environment. The composition can restore spatial memory ability, significantly reduce the escape latency, significantly increase the expression level of hippocampal memory-related proteins, significantly increase the antioxidant capacity of the hippocampus in the brain, and alleviate oxidative damage to the hippocampus. The composite bacterial agent of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can be used to prepare a drug for preventing and treating brain memory dysfunction caused by exposure to a plateau hypoxic environment and a composition thereof, and can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and has very broad application prospects.

The invention discloses application of lactobacillus johnsonii or extracellular vesicles derived from the lactobacillus johnsonii in preparation of medicines for treating and / or preventing adult degenerative scoliosis. Experiments prove that the extracellular vesicles derived from lactobacillus johnsonii can promote synthesis of extracellular matrix (ECM) of nucleus pulposus cells derived from adult degenerative scoliosis (ADS), inhibit ECM degradation and effectively reverse nucleus pulposus ECM metabolism abnormality in the ADS progress process, and prompt that the extracellular vesicles can improve the ADS disease progress by regulating nucleus pulposus cell ECM metabolism.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.